Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2020)
Spero Therapeutics' (SPRO) quarterly Capital Expenditures came in at $12000.0 in Q4 2020, down 90.7% YoY from $129000.0 in Q1 2020, and down 76.47% on a QoQ basis from $51000.0 in Q3 2020.
Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2020) Analysis & Trends
Spero Therapeutics (SPRO) has 5 years of Capital Expenditures data on file, last reported at $12000.0 in Q4 2020.
- Quarterly Capital Expenditures fell 90.7% year-over-year to $12000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $78000.0 (down 71.53% YoY) and the FY2020 annual result came in at $157000.0, down 50.0% from the prior year.
- Capital Expenditures retreated to $12000.0 in Q4 2020, from $51000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q4 2018 to a low of -$1000.0 in Q4 2017.
- A 5-year average of $285909.1 and a median of $79000.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2017 — Capital Expenditures slumped 100.38% — and 2018, when it surged 241500.0%.
- Tracing SPRO's Capital Expenditures over 5 years: stood at $261000.0 in 2016, then tumbled by 100.38% to -$1000.0 in 2017, then surged by 241500.0% to $2.4 million in 2018, then plunged by 94.66% to $129000.0 in 2019, then plunged by 90.7% to $12000.0 in 2020.
- The last three Capital Expenditures figures came in at $12000.0 (Q4 2020), $51000.0 (Q3 2020), and $15000.0 (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 12,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Sep 30, 2020 | 51,000.00 |
| Sep 30, 2020 | 51,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 79,000.00 |
| Mar 31, 2020 | 79,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Jun 30, 2019 | 87,000.00 |
| Jun 30, 2019 | 87,000.00 |
| Mar 31, 2019 | 81,000.00 |
| Mar 31, 2019 | 81,000.00 |
| Dec 31, 2018 | 2.41 Mn |
| Dec 31, 2018 | 2.41 Mn |
| Dec 31, 2017 | -1,000.00 |
| Dec 31, 2017 | -1,000.00 |